NEW YORK (GenomeWeb News) – Genetic Technologies in regulatory documents today said that receipts from customers declined 23 percent year over year during its fiscal second quarter.

For the three months ended Dec. 31, 2012, the Australian company took in A$4.1 million (US$4.3 million) in receipts, down from A$5.3 million in the year-ago period.

Its R&D spending was down 48 percent to A$21,400 from A$41,197 in the year ago period, while advertising and marketing costs were also cut 48 percent to A$217,493 from A$420,274.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.